Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2722fd2ecc8e1e55fbc3bb2ba9fc53fc |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2875 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate |
1997-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92dd9dc3969068b69eb5bd88ca2b2203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f07349a37a3b56739278664111727a9b |
publicationDate |
2007-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CZ-297680-B6 |
titleOfInvention |
A pharmaceutical composition comprising anti-CD40L antibodies or a derivative thereof |
abstract |
The present invention relates to the use of anti-CD40L antibodies for the manufacture of a medicament for the treatment of immunocomplex glomerulonephritis, namely anti-CD40L antibodies that bind a ligand for the CD40 B cell surface molecule and some other cells, or a derivative thereof. Drugs are designed to cure or at least retard or ameliorate the symptoms of nephritis associated with immune system diseases such as lupus or drug-induced serum disease. In particular, drugs containing anti-CD40L antibodies or derivatives thereof are useful (a) to suppress nephritis progression, (b) to stabilize nephritis, or (c) to reverse nephritis. The use of an anti-CD40L antibody for the manufacture of a medicament for administration to an immunocomplexed patient having a renal alostep to suppress the development of immunocomplex glomerulonephritis in a transplanted kidney. |
priorityDate |
1997-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |